We are live on ! Find out more
ARTL icon

Artelo Biosciences
ARTL

15 hedge funds and large institutions have $659K invested in Artelo Biosciences in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

1.02% less ownership

Funds ownership: 4.49% → 3.47% (-1%)

6% less funds holding

Funds holding: 16 → 15 (-1)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

33% less capital invested

Capital invested by funds: $984K → $659K (-$325K)

Holders
15
Holders Change
-1
Holders Change %
-6.25%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCA
Snowden Capital Advisors
New York
+$46.5K
2
Renaissance Technologies
Renaissance Technologies
New York
+$31K
3
HF
HRT Financial
New York
+$12.4K
4
UBS Group
UBS Group
Switzerland
+$8.27K
5
KWP
Keystone Wealth Partners
Arizona
+$6.2K

Top Sellers

Rank Fund Capital Flow
1
KC
Kepos Capital
New York
-$104K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$88.9K
3
VF
Virtu Financial
New York
-$66.2K
4
Citadel Advisors
Citadel Advisors
Florida
-$41K
5
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$14K

ARTL Hedge Fund Activity: Q1 2022 in Review

15 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q1 2022, worth a combined $659K — down 33% from $984K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ARTL and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.

The largest buyer was Snowden Capital Advisors, opening a new position worth an estimated $46.5K. The largest seller was Kepos Capital, exiting entirely with an estimated $104K sold.

  • 15 institutional investors held Artelo Biosciences (ARTL) as of Q1 2022, down from 16 in Q4 2021.
  • Funds reported $659K of Artelo Biosciences stock for Q1 2022, down 33% quarter-over-quarter.
  • 4 funds opened new Artelo Biosciences positions in Q1 2022 and 5 closed out, a net change of -1 holder.
  • The largest Artelo Biosciences buyer in Q1 2022 was Snowden Capital Advisors, an estimated $46.5K added.
  • The largest Artelo Biosciences seller in Q1 2022 was Kepos Capital, an estimated $104K sold.

Based on aggregated 13F filings for Q1 2022.